Home > Rheumatology > ACR 2021 > COVID-19: What You Need to Know > B-cell depleting medication increases COVID-19 breakthrough infection outcome risk

B-cell depleting medication increases COVID-19 breakthrough infection outcome risk

Presented By
Prof. Jean Liew, Boston University, MA, USA
Conference
ACR 2021
Nearly half of the rheumatic patients in need of hospitalisation for a SARS-CoV-2 infection after full vaccination were on treatment with CD20 inhibitors. Additional protective measures for this population at risk should be considered. “COVID-19 vaccinations are recommended and usually well tolerated and efficacious among people with rheumatic disease. However, lab-based studies using surrogate markers of protection against COVID-19 have demonstrated reduced vaccine immunogenicity in people on certain immunosuppressant medications,” Prof. Jean Liew (Boston University, MA, USA) explained the need for further knowledge to effectively counsel immunocompromised patients [1]. The current study analysed data from the Global Rheumatology Alliance registry to shed further light on this matter. The investigation included nearly 200 patients with SARS-CoV-2 infection after vaccination and their outcomes in terms of hospitalisation, the need f...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on